Bellast Ultra L — Double-Polymerization HA Filler for Mid-to-Deep Wrinkles

Bellast Ultra L is the mid-firmness workhorse of the DongkookPharma Bellast range — 20 mg/mL non-animal hyaluronic acid with 0.3% lidocaine, produced via double-polymerization technology. Designed for nasolabial fold correction, lip augmentation, and facial contouring. KFDA + FDA registered with ISO 13485 certification.

Bellast Ultra L Hyaluronic Acid & Lidocaine Filler is manufactured by DongkookPharma Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 1968. The product is part of the Bellast dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · GMP certified · FDA registered · ISO 13485.

Bellast Ultra L Hyaluronic Acid & Lidocaine Filler contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using DongkookPharma Co. Ltd.’s Patented Double Polymerization Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per DongkookPharma Co. Ltd.’s clinical data, Bellast Ultra L Hyaluronic Acid & Lidocaine Filler delivers 9–12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Bellast Ultra L Hyaluronic Acid & Lidocaine Filler is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Bellast Ultra L Hyaluronic Acid & Lidocaine Filler regulatory status: KFDA registered · GMP certified · FDA registered · ISO 13485. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Bellast Ultra L Hyaluronic Acid & Lidocaine Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Bellast Ultra L Hyaluronic Acid & Lidocaine Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Bellast Ultra L Hyaluronic Acid & Lidocaine Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Both products are from DongkookPharma’s HCXL series but differ in HA concentration and intended depth. Soft L (18 mg/mL) targets superficial dermis for fine lines and subtle lip hydration. Ultra L (20 mg/mL) is the mid-firmness variant for mid-to-deep dermal placement — nasolabial folds, lip augmentation, and facial contouring. Practitioners select Soft L for delicate work and Ultra L for moderate-to-severe correction.